Screener
Veracyte VCYT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $1,436,400 | $1,406,019 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $6,908 | $4,593 |
| Accrued liabilities | 43,129 | 48,801 |
| Current portion of deferred revenue | 749 | 1,160 |
| Current portion of acquisition-related contingent consideration | 982 | 1,332 |
| Current portion of operating lease liabilities | 4,347 | 4,051 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's accounts payable?
- Veracyte (VCYT) reported accounts payable of $6.91M in Q1 2026.
- How has Veracyte's accounts payable changed year-over-year?
- Veracyte's accounts payable decreased by 56.0% year-over-year, from $15.71M to $6.91M.
- What is the long-term trend for Veracyte's accounts payable?
- Over 5 years (2020 to 2025), Veracyte's accounts payable has grown at a 8.1% compound annual growth rate (CAGR), from $3.12M to $4.59M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Veracyte's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude